REVOLUTIONIZING THE TREATMENT OF VIRAL EPIDEMICS
A RADICAL, INNOVATIVE WAY TO TREAT RESPIRATORY VIRUS
CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of Covid-19, influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of life-threatening symptoms associated with Covid-19/influenza and Cytokine Releasing Syndrome by modulating the natural immune response to the disease. We are committed to developing first-in-class, best-in-class products that meet a major medical need.
EPIDEMIC: A DEVASTATING PUBLIC HEALTH THREAT
COVID-19 AND INFLUENZA
With the emergence of Covid-19, and the circulation of new, or combined, influenza strains, it is unclear why some viruses induce mild or severe cases of disease in most people, but in other cases induce severe cases of Covid-19 or influenza with devastating results.
The cornerstone of influenza therapy is vaccination and anti-viral medications, both of which have significant limitations. Deaths from Covid-19 and influenza are typically from respiratory symptoms. The respiratory symptoms are a result of the immune system producing cytokines which induce an inflammatory condition. Currently, there are no effective treatments to treat these respiratory symptoms associated with an average of 13M medical visits annually.
CytoAgents' lead drug candidate modulates the body's immune response to reduce tissue damage caused by an excessive immune reaction. This approach would decrease the tissue damage resulting from the excessive release of pro-inflammatory cytokines, known as the cytokine releasing syndrome or "Cytokine Storm", which is induced by Covid-19, influenza, and other viral infections. Our approach to treatment focuses on reducing the destructive impact of the cytokine storm. CytoAgents' approach to therapy is significantly less susceptible to viral mutation and the development of viral resistance.
GP1681: ADDRESSING AN UNMET NEED
CytoAgents' lead candidate, GP1681, addresses a clear unmet need and will expand the category for therapy options available for the treatment of influenza. Additionally, given the mechanism of action, GP1681 may address other conditions associated with cytokine releasing syndrome. There is no therapy for influenza beyond the first 48 hour of influenza symptoms. According to the CDC, last year there were 23M medical visits, 960,000 hospitalizations and 80,000 deaths in the US from influenza. Currently, there are no viable treatment options for the majority of these patients. GP1681 will treat the symptoms by modulating the immune system (unlike anti-viral medications) throughout the course of influenza. Symptoms correlate with cytokine levels and GP1681 decrease the cytokine levels and therefore decrease mortality.
GP1681, is an agonist of a G-protein coupled receptor (GPCR). The expression of this GPCR is dramatically increased during the activation and migration of white blood cells and plays a role in the anti-inflammatory response. GP1681 has been shown to reduce the release of pro-inflammatory cytokines and chemokines from activated, human white blood cells.
GP1681 has an FDA accepted Investigational New Drug (IND) application and is ready to start Phase I human clinical trials.